Relapsing-remitting Multiple Sclerosis Clinical Trial
Official title:
Effects of Sensori-motor Integration Balance Training on Balance Disturbances in Patients With Multiple Sclerosis
Balance impairment is a common and very disabling disturbance in people with Multiple Sclerosis. The efficacy of pharmacotherapy in treating balance impairment in MS is poorly documented in literature. Although literature dealing with the rehabilitation of balance impairment in MS is very scant, the preliminary data reports show very promising results. The present project could have a positive impact on balance and gait ability, disability, fear of falling, risk of falls and quality of life of patients with Multiple Sclerosis.
| Status | Completed |
| Enrollment | 80 |
| Est. completion date | January 2012 |
| Est. primary completion date | October 2011 |
| Accepts healthy volunteers | No |
| Gender | Both |
| Age group | 18 Years to 65 Years |
| Eligibility |
Inclusion Criteria: - Age < 65 years - Expanded Disability Status Scale (EDSS) 2.0 > score < 6.0 (24) - Mini Mental State Evaluation (MMSE) score = 24 - Absence of cognitive impairment - Absence of heart problems - Self-reported sensation of postural instability - Ability to maintain standing position without aids for at least 1 minute - Ability to walk independently for at least 15 metres Exclusion Criteria: - Disease recurrence that worsens significantly during the 3 months prior to recruitment - Pharmacological therapy not well defined - Presence of vestibular disorders and/or paroxysmal vertigo - Performance of any type of rehabilitation treatment in the month prior to recruitment - Presence of other concurrent neurological or orthopaedic diseases involving the lower limbs and/or interfering with standing position and/or walking. |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment
| Country | Name | City | State |
|---|---|---|---|
| Italy | S.S.O. di Riabilitazione dell'Ospedale Policlinico | Verona | |
| Italy | Section of Clinical Neurology, Department Neurological, Neuropsychological, Morphological and Movement Sciences, University of Verona, Verona, Italy | Verona |
| Lead Sponsor | Collaborator |
|---|---|
| Universita di Verona |
Italy,
Cattaneo D, Jonsdottir J, Zocchi M, Regola A. Effects of balance exercises on people with multiple sclerosis: a pilot study. Clin Rehabil. 2007 Sep;21(9):771-81. — View Citation
Cattaneo D, Jonsdottir J. Sensory impairments in quiet standing in subjects with multiple sclerosis. Mult Scler. 2009 Jan;15(1):59-67. doi: 10.1177/1352458508096874. Epub 2008 Oct 9. — View Citation
Smania N, Picelli A, Gandolfi M, Fiaschi A, Tinazzi M. Rehabilitation of sensorimotor integration deficits in balance impairment of patients with stroke hemiparesis: a before/after pilot study. Neurol Sci. 2008 Oct;29(5):313-9. doi: 10.1007/s10072-008-0988-0. Epub 2008 Oct 21. — View Citation
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Clinical assessment procedures: - Berg Balance Scale (BBS) - Activities-specific Balance Confidence Scale (ABC) Instrumental assessment procedures: - Stabilometric assessment | At recruitment, after treatment (5 weeks) and in the follow-up (1 month) | Yes | |
| Secondary | Clinical evaluation - Walking evaluation - Multiple Sclerosis Quality Of Life-54 (MSQOL-54) - Fatigue Severity Scale (FSS) - Postural Transfers | At recruitment, after treatment (5 weeks) and in the follow-up (1 month) | Yes |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02549703 -
Mitochondrial Dysfunction and Disease Progression
|
||
| Completed |
NCT02293967 -
Mass Balance Study of MT-1303
|
Phase 1 | |
| Terminated |
NCT02222948 -
Efficacy and Safety of Vatelizumab in Patients With Relapsing-Remitting Multiple Sclerosis
|
Phase 2 | |
| Terminated |
NCT01790269 -
Monitoring Natural Killer Cells in Multiple Sclerosis Patients Treated With Fingolimod
|
||
| Terminated |
NCT01701856 -
Natalizumab De-escalation to Interferon-beta-1b in Patients With Relapsing-remitting Multiple Sclerosis
|
Phase 4 | |
| Completed |
NCT00525668 -
Sunphenon Epigallocatechin-gallate (EGCg) in Relapsing-remitting Multiple Sclerosis (SuniMS Study)
|
Phase 1/Phase 2 | |
| Terminated |
NCT00398528 -
An fMRI Study of Treatment Optimization Comparing Two Disease Modifying Therapies Used to Treat Relapsing Remitting Multiple Sclerosis
|
Phase 4 | |
| Completed |
NCT00315367 -
A fMRI(Functional Magnetic Resonance Imaging) Research Study to Learn More About Multiple Sclerosis and Individuals Potentially Experiencing Memory Difficulties
|
Phase 4 | |
| Terminated |
NCT04032171 -
Study of Evobrutinib in Participants With RMS
|
Phase 3 | |
| Completed |
NCT01930708 -
A Study Evaluating the Effectiveness of Tecfidera (Dimethyl Fumarate) on Multiple Sclerosis (MS) Disease Activity and Patient-Reported Outcomes
|
Phase 4 | |
| Completed |
NCT03000647 -
Guided Versus Non-guided Pelvic Floor Exercises for Urinary Incontinence in Relapsing-Remitting Multiple Sclerosis
|
N/A | |
| Completed |
NCT02205489 -
Management Of The Infusion-Associated Reactions In RRMS Patients Treated With LEMTRADA
|
Phase 4 | |
| Completed |
NCT02753088 -
Efficacy and Safety of BCD-063 and Copaxone-Teva in Patients With Relapsing-Remitting Multiple Sclerosis
|
Phase 3 | |
| Recruiting |
NCT01466114 -
Estriol Treatment in Multiple Sclerosis (MS): Effect on Cognition
|
Phase 2 | |
| Completed |
NCT01244139 -
Safety Study of BIIB033 in Subjects With Multiple Sclerosis
|
Phase 1 | |
| Completed |
NCT01416155 -
Extension Study to Evaluate Safety and Efficacy of Natalizumab in Japanese Participants With Relapsing-Remitting Multiple Sclerosis
|
Phase 2 | |
| Completed |
NCT00559702 -
Safety Study of Natalizumab to Treat Multiple Sclerosis (MS)
|
Phase 1 | |
| Completed |
NCT00493116 -
Is IFN-beta Treatment in MS Useful After a Washout Period in Patients With Neutralizing Antibodies to Interferon Beta
|
Phase 4 | |
| Terminated |
NCT01706107 -
Canadian Multicenter Observational Study of Tysabri in Early Relapsing Remitting Multiple Sclerosis Participants
|
||
| Completed |
NCT01943526 -
Ireland Natalizumab (TYSABRI) Observational Program
|